Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical
Trial: A Report from the European Paediatric Soft Tissue
Sarcoma Study Group (EpSSG)

J 2024

Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

CHISHOLM, Julia; Henry MANDEVILLE; Madeleine ADAMS; Veronique MINARD-COLLIN; Timothy ROGERS et. al.

Základní údaje

Originální název

Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Autoři

Vydání

Advances in Gastrointestinal Cancers, BASEL, Mediscript Ltd. 2024, 1479-9995

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

FaR-RMS

Kód RIV

RIV/00216224:90034/24:00138211

Organizační jednotka

CZECRIN

DOI

https://doi.org/10.3390/cancers16050998

UT WoS

001183370200001

Klíčová slova česky

rhabdomyosarcoma; clinical trial; chemotherapy; radiotherapy; randomisation; novel agents; FaR-RMS; EpSSG

Klíčová slova anglicky

rhabdomyosarcoma; clinical trial; chemotherapy; radiotherapy; randomisation; novel agents; FaR-RMS; EpSSG

Štítky

CZECRIN, Excelence Science, RIV, user, článek v časopise

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 27. 2. 2025 10:16, Bc. Hana Vladíková, BBA

Anotace

V originále

The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease. Additional sub-studies focusing on biological risk stratification, use of imaging modalities, including [F-18]FDG PET-CT and diffusion-weighted MRI imaging (DWI) as prognostic markers, and impact of therapy on quality of life are described. This paper forms part of a Special Issue on rhabdomyosarcoma and outlines the study background, rationale for randomisations and sub-studies, design, and plans for utilisation and dissemination of results.

Návaznosti

90249, velká výzkumná infrastruktura

Název: CZECRIN IV

Citovat

CHISHOLM, Julia; Henry MANDEVILLE; Madeleine ADAMS; Veronique MINARD-COLLIN; Timothy ROGERS; Anna KELSEY; Janet SHIPLEY; van Rick R. RIJN; de Vries ISABELLE; van Ewijk ROELOF; de Keizer BART; Susanne A GATZ; Michela CASANOVA; Lisa Lyngsie HJALGRIM; Charlotte FIRTH; Keith WHEATLEY; Pamela KEARNS; Wenyu LIU; Amanda KIRKHAM; Helen REES; Gianni BISOGNO; Ajla WASTI; Sara WAKELING; Delphine HEENEN; Deborah A TWEDDLE; Johannes H M MERKS a Meriel JENNEY. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Advances in Gastrointestinal Cancers. BASEL: Mediscript Ltd., 2024, roč. 16, č. 5, s. 1-24. ISSN 1479-9995. Dostupné z: https://doi.org/10.3390/cancers16050998.

@article{2464268,
   author = {Chisholm, Julia and Mandeville, Henry and Adams, Madeleine and MinardandCollin, Veronique and Rogers, Timothy and Kelsey, Anna and Shipley, Janet and Rijn, van Rick R. and Isabelle, de Vries and Roelof, van Ewijk and Bart, de Keizer and Gatz, Susanne A and Casanova, Michela and Hjalgrim, Lisa Lyngsie and Firth, Charlotte and Wheatley, Keith and Kearns, Pamela and Liu, Wenyu and Kirkham, Amanda and Rees, Helen and Bisogno, Gianni and Wasti, Ajla and Wakeling, Sara and Heenen, Delphine and Tweddle, Deborah A and Merks, Johannes H M and Jenney, Meriel},
   article_location = {BASEL},
   article_number = {5},
   doi = {https://doi.org/10.3390/cancers16050998},
   keywords = {rhabdomyosarcoma; clinical trial; chemotherapy; radiotherapy; randomisation; novel agents; FaR-RMS; EpSSG},
   language = {eng},
   issn = {1479-9995},
   journal = {Advances in Gastrointestinal Cancers},
   title = {Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)},
   url = {https://www.webofscience.com/wos/woscc/full-record/WOS:001183370200001},
   volume = {16},
   year = {2024}
}

TY  - JOUR
ID  - 2464268
AU  - Chisholm, Julia - Mandeville, Henry - Adams, Madeleine - Minard-Collin, Veronique - Rogers, Timothy - Kelsey, Anna - Shipley, Janet - Rijn, van Rick R. - Isabelle, de Vries - Roelof, van Ewijk - Bart, de Keizer - Gatz, Susanne A - Casanova, Michela - Hjalgrim, Lisa Lyngsie - Firth, Charlotte - Wheatley, Keith - Kearns, Pamela - Liu, Wenyu - Kirkham, Amanda - Rees, Helen - Bisogno, Gianni - Wasti, Ajla - Wakeling, Sara - Heenen, Delphine - Tweddle, Deborah A - Merks, Johannes H M - Jenney, Meriel
PY  - 2024
TI  - Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)
JF  - Advances in Gastrointestinal Cancers
VL  - 16
IS  - 5
SP  - 1-24
EP  - 1-24
PB  - Mediscript Ltd.
SN  - 14799995
KW  - rhabdomyosarcoma
KW  - clinical trial
KW  - chemotherapy
KW  - radiotherapy
KW  - randomisation
KW  - novel agents
KW  - FaR-RMS
KW  - EpSSG
UR  - https://www.webofscience.com/wos/woscc/full-record/WOS:001183370200001
N2  - The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease. Additional sub-studies focusing on biological risk stratification, use of imaging modalities, including [F-18]FDG PET-CT and diffusion-weighted MRI imaging (DWI) as prognostic markers, and impact of therapy on quality of life are described. This paper forms part of a Special Issue on rhabdomyosarcoma and outlines the study background, rationale for randomisations and sub-studies, design, and plans for utilisation and dissemination of results.
ER  -

CHISHOLM, Julia; Henry MANDEVILLE; Madeleine ADAMS; Veronique MINARD-COLLIN; Timothy ROGERS; Anna KELSEY; Janet SHIPLEY; van Rick R. RIJN; de Vries ISABELLE; van Ewijk ROELOF; de Keizer BART; Susanne A GATZ; Michela CASANOVA; Lisa Lyngsie HJALGRIM; Charlotte FIRTH; Keith WHEATLEY; Pamela KEARNS; Wenyu LIU; Amanda KIRKHAM; Helen REES; Gianni BISOGNO; Ajla WASTI; Sara WAKELING; Delphine HEENEN; Deborah A TWEDDLE; Johannes H M MERKS a Meriel JENNEY. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). \textit{Advances in Gastrointestinal Cancers}. BASEL: Mediscript Ltd., 2024, roč.~16, č.~5, s.~1-24. ISSN~1479-9995. Dostupné z: https://doi.org/10.3390/cancers16050998.

Přehled o publikaci